文献速递药疹与重症皮肤不良反应皮肤肿瘤

癌症类型和组织学影响免疫治疗皮肤毒性:多中心队列研究

Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
PubMed 文献 · Br J Dermatol · 2024-01-01

该回顾性队列研究纳入2011至2020年接受免疫检查点抑制剂治疗的3668例患者,其中669例发生皮肤免疫相关不良事件。多变量Cox模型显示,皮肤鳞状细胞癌、黑色素瘤、头颈腺癌、泌尿移行细胞癌和泌尿腺癌的cirAE风险显著升高。cirAE风险增加转化为黑色素瘤和cSCC的调整生存获益。

要点

  • 皮肤鳞状细胞癌和黑色素瘤患者发生cirAE风险最高。
  • cirAE风险增加与黑色素瘤和cSCC的生存获益相关。
  • 对高风险患者应加强咨询和皮肤科监测。

核心结论

  • 接受ICI治疗的皮肤恶性肿瘤患者cirAE发生率最高,并伴随生存获益。

研究设计与样本

  • 使用多变量Cox比例风险模型分析癌症器官系统和组织学对cirAE发展的影响。
  • 使用时间变化Cox比例风险模型分析cirAE对死亡率的影响。

主要发现

  • 669例患者发生cirAE。
  • 与其他非上皮性癌症相比,cSCC的cirAE风险HR为3.57(P < 0.001)。
  • 黑色素瘤的cirAE风险HR为2.09(P < 0.001)。
  • 头颈腺癌的cirAE风险HR为2.13(P = 0.009)。
  • 泌尿移行细胞癌的cirAE风险HR为2.15(P < 0.001),泌尿腺癌的HR为1.53(P = 0.037)。

关键数值与推荐

  • 黑色素瘤的调整生存获益HR为0.37(P < 0.001)。
  • cSCC的调整生存获益HR为0.51(P = 0.011)。

临床怎么用

  • 对黑色素瘤和cSCC等高风险患者加强咨询和皮肤科监测。

局限性

  • 回顾性研究设计。
  • 队列来自单一地理区域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in the setting of immune checkpoint inhibitor (ICI) therapy. Identifying patients who are at increased risk of developing cirAEs may improve quality of life and outcomes. OBJECTIVES: To investigate the influence of cancer type and histology on the development of cirAEs in the setting of ICI therapy and survival outcomes. METHODS: This retrospective cohort study included patients recruited between 1 December 2011 and 30 October 2020. They received ICI from 2011 to 2020 with follow-up of outcomes through October 2021. We identified 3668 recipients of ICI therapy who were seen at Massachusetts General Brigham and Dana-Farber. Of these, 669 developed cirAEs. Records that were incomplete or categories of insufficient sample size were excluded from the study cohort. Multivariate Cox proportional hazards models were used to investigate the impact of cancer organ system and histology on cirAE development, after adjusting for demographics, Charlson Comorbidity Index, ICI type, cancer stage at ICI initiation, and year of ICI initiation. Time-varying Cox proportional hazards modelling was used to examine the impact of cirAE development on mortality. RESULTS: Compared with other nonepithelial cancers (neuroendocrine, leukaemia, lymphoma, myeloma, sarcoma and central nervous system malignancies), cutaneous squamous cell carcinoma [cSCC; hazard ratio (HR) 3.57, P < 0.001], melanoma (HR 2.09, P < 0.001), head and neck adenocarcinoma (HR 2.13, P = 0.009), genitourinary transitional cell carcinoma (HR 2.15, P < 0.001) and genitourinary adenocarcinoma (HR 1.53, P = 0.037) were at significantly higher risk of cirAEs in multivariate analyses. The increased risk of cirAEs translated into an adjusted survival benefit for melanoma (HR 0.37, P < 0.001) and cSCC (HR 0.51, P = 0.011). CONCLUSIONS: The highest rate of cirAEs and subsequent survival benefits were observed in cutaneous malignancies treated with ICI therapies. This study improves our understanding of patients who are at highest risk of developing cirAEs and would, therefore, benefit from appropriate counselling and closer monitoring by their oncologists and dermatologists throughout their ICI therapy. Limitations include its retrospective nature and cohort from one geography. Cutaneous immune-related adverse events (cirAEs) are the most common complications to occur for oncology patients treated with immune checkpoint inhibitors (ICIs). cirAEs can lead to increased use of healthcare resources and significant morbidity. Identifying patients who are at increased risk of developing cirAEs may improve quality of life and outcomes. In this study, we aimed to investigate the influence of cancer organ system and histology on the development of cirAEs and survival outcomes. To do this, we included a cohort of patients retrospectively between 1 December 2011 and 30 October 2020. We identified 3668 ICI recipients who were seen at Massachusetts General Brigham and Dana-Farber in Boston, Massachusetts. Of these, 669 people developed cirAEs. Multivariate Cox proportional hazards models were used to investigate the impact of cancer organ system and histology on cirAE development, after adjusting for demographics, Charlson Comorbidity Index, ICI type, cancer stage at ICI start, and year of ICI initiation. Time-varying Cox proportional hazards modelling was used to examine the impact of cirAE development on mortality. We found that, compared with other nonepithelial cancers, patients with cutaneous squamous cell carcinoma (cSCC) and melanoma were at significantly higher risk of cirAEs. The increased risk of cirAEs translated into an adjusted survival benefit for melanoma and cSCC. This study improves our understanding of patients who are at highest risk of developing cirAEs – those with melanoma and cSCC. Therefore, many patients could benefit from appropriate counselling and close monitoring by their oncologists and dermatologists throughout ICI therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan G, Khattab S, Leung BW, et al. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study. Br J Dermatol. 2024. PMID: 38366637. doi:10.1093/bjd/ljae053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。